Feverish Quest for Ebola Immunotherapy: Straight or Cocktail?
The ebolavirus immunotherapeutics field has replaced previous perceptions of antibody inadequacy with a new abundance of monoclonals exhibiting post exposure efficacy. Now the questions are: what epitopes to target, what immunological mechanisms to seek, whether species-specific or broadly reactive...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Saphire, Erica Ollmann [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2016 |
|---|
| Umfang: |
3 |
|---|
| Übergeordnetes Werk: |
Enthalten in: TCT-610 Long-Term Outcomes of Complete Versus Incomplete Revascularization After Drug-Eluting Stent Implantation in Patients with Multivessel Coronary Disease - Gao, Zhan ELSEVIER, 2012, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:24 ; year:2016 ; number:9 ; pages:684-686 ; extent:3 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.tim.2016.05.008 |
|---|
| Katalog-ID: |
ELV040144925 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV040144925 | ||
| 003 | DE-627 | ||
| 005 | 20230624071056.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180603s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.tim.2016.05.008 |2 doi | |
| 028 | 5 | 2 | |a GBV00000000000145A.pica |
| 035 | |a (DE-627)ELV040144925 | ||
| 035 | |a (ELSEVIER)S0966-842X(16)30049-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 570 | |
| 082 | 0 | 4 | |a 570 |q DE-600 |
| 082 | 0 | 4 | |a 610 |q VZ |
| 082 | 0 | 4 | |a 600 |a 690 |q VZ |
| 084 | |a 51.00 |2 bkl | ||
| 084 | |a 51.32 |2 bkl | ||
| 100 | 1 | |a Saphire, Erica Ollmann |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Feverish Quest for Ebola Immunotherapy: Straight or Cocktail? |
| 264 | 1 | |c 2016 | |
| 300 | |a 3 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a The ebolavirus immunotherapeutics field has replaced previous perceptions of antibody inadequacy with a new abundance of monoclonals exhibiting post exposure efficacy. Now the questions are: what epitopes to target, what immunological mechanisms to seek, whether species-specific or broadly reactive antibodies are best, and whether a cocktail or monotherapy should be used. | ||
| 700 | 1 | |a Aman, M. Javad |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier Science |a Gao, Zhan ELSEVIER |t TCT-610 Long-Term Outcomes of Complete Versus Incomplete Revascularization After Drug-Eluting Stent Implantation in Patients with Multivessel Coronary Disease |d 2012 |g Amsterdam [u.a.] |w (DE-627)ELV016273370 |
| 773 | 1 | 8 | |g volume:24 |g year:2016 |g number:9 |g pages:684-686 |g extent:3 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.tim.2016.05.008 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a GBV_ILN_20 | ||
| 912 | |a GBV_ILN_72 | ||
| 912 | |a GBV_ILN_120 | ||
| 936 | b | k | |a 51.00 |j Werkstoffkunde: Allgemeines |q VZ |
| 936 | b | k | |a 51.32 |j Werkstoffmechanik |q VZ |
| 951 | |a AR | ||
| 952 | |d 24 |j 2016 |e 9 |h 684-686 |g 3 | ||
| 953 | |2 045F |a 570 | ||
| author_variant |
e o s eo eos |
|---|---|
| matchkey_str |
saphireericaollmannamanmjavad:2016----:eeihusfrblimnteayta |
| hierarchy_sort_str |
2016 |
| bklnumber |
51.00 51.32 |
| publishDate |
2016 |
| allfields |
10.1016/j.tim.2016.05.008 doi GBV00000000000145A.pica (DE-627)ELV040144925 (ELSEVIER)S0966-842X(16)30049-X DE-627 ger DE-627 rakwb eng 570 570 DE-600 610 VZ 600 690 VZ 51.00 bkl 51.32 bkl Saphire, Erica Ollmann verfasserin aut Feverish Quest for Ebola Immunotherapy: Straight or Cocktail? 2016 3 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The ebolavirus immunotherapeutics field has replaced previous perceptions of antibody inadequacy with a new abundance of monoclonals exhibiting post exposure efficacy. Now the questions are: what epitopes to target, what immunological mechanisms to seek, whether species-specific or broadly reactive antibodies are best, and whether a cocktail or monotherapy should be used. Aman, M. Javad oth Enthalten in Elsevier Science Gao, Zhan ELSEVIER TCT-610 Long-Term Outcomes of Complete Versus Incomplete Revascularization After Drug-Eluting Stent Implantation in Patients with Multivessel Coronary Disease 2012 Amsterdam [u.a.] (DE-627)ELV016273370 volume:24 year:2016 number:9 pages:684-686 extent:3 https://doi.org/10.1016/j.tim.2016.05.008 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_20 GBV_ILN_72 GBV_ILN_120 51.00 Werkstoffkunde: Allgemeines VZ 51.32 Werkstoffmechanik VZ AR 24 2016 9 684-686 3 045F 570 |
| spelling |
10.1016/j.tim.2016.05.008 doi GBV00000000000145A.pica (DE-627)ELV040144925 (ELSEVIER)S0966-842X(16)30049-X DE-627 ger DE-627 rakwb eng 570 570 DE-600 610 VZ 600 690 VZ 51.00 bkl 51.32 bkl Saphire, Erica Ollmann verfasserin aut Feverish Quest for Ebola Immunotherapy: Straight or Cocktail? 2016 3 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The ebolavirus immunotherapeutics field has replaced previous perceptions of antibody inadequacy with a new abundance of monoclonals exhibiting post exposure efficacy. Now the questions are: what epitopes to target, what immunological mechanisms to seek, whether species-specific or broadly reactive antibodies are best, and whether a cocktail or monotherapy should be used. Aman, M. Javad oth Enthalten in Elsevier Science Gao, Zhan ELSEVIER TCT-610 Long-Term Outcomes of Complete Versus Incomplete Revascularization After Drug-Eluting Stent Implantation in Patients with Multivessel Coronary Disease 2012 Amsterdam [u.a.] (DE-627)ELV016273370 volume:24 year:2016 number:9 pages:684-686 extent:3 https://doi.org/10.1016/j.tim.2016.05.008 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_20 GBV_ILN_72 GBV_ILN_120 51.00 Werkstoffkunde: Allgemeines VZ 51.32 Werkstoffmechanik VZ AR 24 2016 9 684-686 3 045F 570 |
| allfields_unstemmed |
10.1016/j.tim.2016.05.008 doi GBV00000000000145A.pica (DE-627)ELV040144925 (ELSEVIER)S0966-842X(16)30049-X DE-627 ger DE-627 rakwb eng 570 570 DE-600 610 VZ 600 690 VZ 51.00 bkl 51.32 bkl Saphire, Erica Ollmann verfasserin aut Feverish Quest for Ebola Immunotherapy: Straight or Cocktail? 2016 3 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The ebolavirus immunotherapeutics field has replaced previous perceptions of antibody inadequacy with a new abundance of monoclonals exhibiting post exposure efficacy. Now the questions are: what epitopes to target, what immunological mechanisms to seek, whether species-specific or broadly reactive antibodies are best, and whether a cocktail or monotherapy should be used. Aman, M. Javad oth Enthalten in Elsevier Science Gao, Zhan ELSEVIER TCT-610 Long-Term Outcomes of Complete Versus Incomplete Revascularization After Drug-Eluting Stent Implantation in Patients with Multivessel Coronary Disease 2012 Amsterdam [u.a.] (DE-627)ELV016273370 volume:24 year:2016 number:9 pages:684-686 extent:3 https://doi.org/10.1016/j.tim.2016.05.008 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_20 GBV_ILN_72 GBV_ILN_120 51.00 Werkstoffkunde: Allgemeines VZ 51.32 Werkstoffmechanik VZ AR 24 2016 9 684-686 3 045F 570 |
| allfieldsGer |
10.1016/j.tim.2016.05.008 doi GBV00000000000145A.pica (DE-627)ELV040144925 (ELSEVIER)S0966-842X(16)30049-X DE-627 ger DE-627 rakwb eng 570 570 DE-600 610 VZ 600 690 VZ 51.00 bkl 51.32 bkl Saphire, Erica Ollmann verfasserin aut Feverish Quest for Ebola Immunotherapy: Straight or Cocktail? 2016 3 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The ebolavirus immunotherapeutics field has replaced previous perceptions of antibody inadequacy with a new abundance of monoclonals exhibiting post exposure efficacy. Now the questions are: what epitopes to target, what immunological mechanisms to seek, whether species-specific or broadly reactive antibodies are best, and whether a cocktail or monotherapy should be used. Aman, M. Javad oth Enthalten in Elsevier Science Gao, Zhan ELSEVIER TCT-610 Long-Term Outcomes of Complete Versus Incomplete Revascularization After Drug-Eluting Stent Implantation in Patients with Multivessel Coronary Disease 2012 Amsterdam [u.a.] (DE-627)ELV016273370 volume:24 year:2016 number:9 pages:684-686 extent:3 https://doi.org/10.1016/j.tim.2016.05.008 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_20 GBV_ILN_72 GBV_ILN_120 51.00 Werkstoffkunde: Allgemeines VZ 51.32 Werkstoffmechanik VZ AR 24 2016 9 684-686 3 045F 570 |
| allfieldsSound |
10.1016/j.tim.2016.05.008 doi GBV00000000000145A.pica (DE-627)ELV040144925 (ELSEVIER)S0966-842X(16)30049-X DE-627 ger DE-627 rakwb eng 570 570 DE-600 610 VZ 600 690 VZ 51.00 bkl 51.32 bkl Saphire, Erica Ollmann verfasserin aut Feverish Quest for Ebola Immunotherapy: Straight or Cocktail? 2016 3 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The ebolavirus immunotherapeutics field has replaced previous perceptions of antibody inadequacy with a new abundance of monoclonals exhibiting post exposure efficacy. Now the questions are: what epitopes to target, what immunological mechanisms to seek, whether species-specific or broadly reactive antibodies are best, and whether a cocktail or monotherapy should be used. Aman, M. Javad oth Enthalten in Elsevier Science Gao, Zhan ELSEVIER TCT-610 Long-Term Outcomes of Complete Versus Incomplete Revascularization After Drug-Eluting Stent Implantation in Patients with Multivessel Coronary Disease 2012 Amsterdam [u.a.] (DE-627)ELV016273370 volume:24 year:2016 number:9 pages:684-686 extent:3 https://doi.org/10.1016/j.tim.2016.05.008 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_20 GBV_ILN_72 GBV_ILN_120 51.00 Werkstoffkunde: Allgemeines VZ 51.32 Werkstoffmechanik VZ AR 24 2016 9 684-686 3 045F 570 |
| language |
English |
| source |
Enthalten in TCT-610 Long-Term Outcomes of Complete Versus Incomplete Revascularization After Drug-Eluting Stent Implantation in Patients with Multivessel Coronary Disease Amsterdam [u.a.] volume:24 year:2016 number:9 pages:684-686 extent:3 |
| sourceStr |
Enthalten in TCT-610 Long-Term Outcomes of Complete Versus Incomplete Revascularization After Drug-Eluting Stent Implantation in Patients with Multivessel Coronary Disease Amsterdam [u.a.] volume:24 year:2016 number:9 pages:684-686 extent:3 |
| format_phy_str_mv |
Article |
| bklname |
Werkstoffkunde: Allgemeines Werkstoffmechanik |
| institution |
findex.gbv.de |
| dewey-raw |
570 |
| isfreeaccess_bool |
false |
| container_title |
TCT-610 Long-Term Outcomes of Complete Versus Incomplete Revascularization After Drug-Eluting Stent Implantation in Patients with Multivessel Coronary Disease |
| authorswithroles_txt_mv |
Saphire, Erica Ollmann @@aut@@ Aman, M. Javad @@oth@@ |
| publishDateDaySort_date |
2016-01-01T00:00:00Z |
| hierarchy_top_id |
ELV016273370 |
| dewey-sort |
3570 |
| id |
ELV040144925 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV040144925</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230624071056.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2016 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.tim.2016.05.008</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBV00000000000145A.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV040144925</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0966-842X(16)30049-X</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">570</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">570</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">600</subfield><subfield code="a">690</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">51.00</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">51.32</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Saphire, Erica Ollmann</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Feverish Quest for Ebola Immunotherapy: Straight or Cocktail?</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2016</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">3</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The ebolavirus immunotherapeutics field has replaced previous perceptions of antibody inadequacy with a new abundance of monoclonals exhibiting post exposure efficacy. Now the questions are: what epitopes to target, what immunological mechanisms to seek, whether species-specific or broadly reactive antibodies are best, and whether a cocktail or monotherapy should be used.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Aman, M. Javad</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Gao, Zhan ELSEVIER</subfield><subfield code="t">TCT-610 Long-Term Outcomes of Complete Versus Incomplete Revascularization After Drug-Eluting Stent Implantation in Patients with Multivessel Coronary Disease</subfield><subfield code="d">2012</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV016273370</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:24</subfield><subfield code="g">year:2016</subfield><subfield code="g">number:9</subfield><subfield code="g">pages:684-686</subfield><subfield code="g">extent:3</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.tim.2016.05.008</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_72</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_120</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">51.00</subfield><subfield code="j">Werkstoffkunde: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">51.32</subfield><subfield code="j">Werkstoffmechanik</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">24</subfield><subfield code="j">2016</subfield><subfield code="e">9</subfield><subfield code="h">684-686</subfield><subfield code="g">3</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">570</subfield></datafield></record></collection>
|
| author |
Saphire, Erica Ollmann |
| spellingShingle |
Saphire, Erica Ollmann ddc 570 ddc 610 ddc 600 bkl 51.00 bkl 51.32 Feverish Quest for Ebola Immunotherapy: Straight or Cocktail? |
| authorStr |
Saphire, Erica Ollmann |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV016273370 |
| format |
electronic Article |
| dewey-ones |
570 - Life sciences; biology 610 - Medicine & health 600 - Technology 690 - Buildings |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
570 570 DE-600 610 VZ 600 690 VZ 51.00 bkl 51.32 bkl Feverish Quest for Ebola Immunotherapy: Straight or Cocktail? |
| topic |
ddc 570 ddc 610 ddc 600 bkl 51.00 bkl 51.32 |
| topic_unstemmed |
ddc 570 ddc 610 ddc 600 bkl 51.00 bkl 51.32 |
| topic_browse |
ddc 570 ddc 610 ddc 600 bkl 51.00 bkl 51.32 |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
m j a mj mja |
| hierarchy_parent_title |
TCT-610 Long-Term Outcomes of Complete Versus Incomplete Revascularization After Drug-Eluting Stent Implantation in Patients with Multivessel Coronary Disease |
| hierarchy_parent_id |
ELV016273370 |
| dewey-tens |
570 - Life sciences; biology 610 - Medicine & health 600 - Technology 690 - Building & construction |
| hierarchy_top_title |
TCT-610 Long-Term Outcomes of Complete Versus Incomplete Revascularization After Drug-Eluting Stent Implantation in Patients with Multivessel Coronary Disease |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV016273370 |
| title |
Feverish Quest for Ebola Immunotherapy: Straight or Cocktail? |
| ctrlnum |
(DE-627)ELV040144925 (ELSEVIER)S0966-842X(16)30049-X |
| title_full |
Feverish Quest for Ebola Immunotherapy: Straight or Cocktail? |
| author_sort |
Saphire, Erica Ollmann |
| journal |
TCT-610 Long-Term Outcomes of Complete Versus Incomplete Revascularization After Drug-Eluting Stent Implantation in Patients with Multivessel Coronary Disease |
| journalStr |
TCT-610 Long-Term Outcomes of Complete Versus Incomplete Revascularization After Drug-Eluting Stent Implantation in Patients with Multivessel Coronary Disease |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
500 - Science 600 - Technology |
| recordtype |
marc |
| publishDateSort |
2016 |
| contenttype_str_mv |
zzz |
| container_start_page |
684 |
| author_browse |
Saphire, Erica Ollmann |
| container_volume |
24 |
| physical |
3 |
| class |
570 570 DE-600 610 VZ 600 690 VZ 51.00 bkl 51.32 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Saphire, Erica Ollmann |
| doi_str_mv |
10.1016/j.tim.2016.05.008 |
| dewey-full |
570 610 600 690 |
| title_sort |
feverish quest for ebola immunotherapy: straight or cocktail? |
| title_auth |
Feverish Quest for Ebola Immunotherapy: Straight or Cocktail? |
| abstract |
The ebolavirus immunotherapeutics field has replaced previous perceptions of antibody inadequacy with a new abundance of monoclonals exhibiting post exposure efficacy. Now the questions are: what epitopes to target, what immunological mechanisms to seek, whether species-specific or broadly reactive antibodies are best, and whether a cocktail or monotherapy should be used. |
| abstractGer |
The ebolavirus immunotherapeutics field has replaced previous perceptions of antibody inadequacy with a new abundance of monoclonals exhibiting post exposure efficacy. Now the questions are: what epitopes to target, what immunological mechanisms to seek, whether species-specific or broadly reactive antibodies are best, and whether a cocktail or monotherapy should be used. |
| abstract_unstemmed |
The ebolavirus immunotherapeutics field has replaced previous perceptions of antibody inadequacy with a new abundance of monoclonals exhibiting post exposure efficacy. Now the questions are: what epitopes to target, what immunological mechanisms to seek, whether species-specific or broadly reactive antibodies are best, and whether a cocktail or monotherapy should be used. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_20 GBV_ILN_72 GBV_ILN_120 |
| container_issue |
9 |
| title_short |
Feverish Quest for Ebola Immunotherapy: Straight or Cocktail? |
| url |
https://doi.org/10.1016/j.tim.2016.05.008 |
| remote_bool |
true |
| author2 |
Aman, M. Javad |
| author2Str |
Aman, M. Javad |
| ppnlink |
ELV016273370 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth |
| doi_str |
10.1016/j.tim.2016.05.008 |
| up_date |
2024-07-06T16:45:56.861Z |
| _version_ |
1803848889784074240 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV040144925</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230624071056.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2016 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.tim.2016.05.008</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBV00000000000145A.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV040144925</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0966-842X(16)30049-X</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">570</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">570</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">600</subfield><subfield code="a">690</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">51.00</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">51.32</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Saphire, Erica Ollmann</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Feverish Quest for Ebola Immunotherapy: Straight or Cocktail?</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2016</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">3</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The ebolavirus immunotherapeutics field has replaced previous perceptions of antibody inadequacy with a new abundance of monoclonals exhibiting post exposure efficacy. Now the questions are: what epitopes to target, what immunological mechanisms to seek, whether species-specific or broadly reactive antibodies are best, and whether a cocktail or monotherapy should be used.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Aman, M. Javad</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Gao, Zhan ELSEVIER</subfield><subfield code="t">TCT-610 Long-Term Outcomes of Complete Versus Incomplete Revascularization After Drug-Eluting Stent Implantation in Patients with Multivessel Coronary Disease</subfield><subfield code="d">2012</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV016273370</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:24</subfield><subfield code="g">year:2016</subfield><subfield code="g">number:9</subfield><subfield code="g">pages:684-686</subfield><subfield code="g">extent:3</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.tim.2016.05.008</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_72</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_120</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">51.00</subfield><subfield code="j">Werkstoffkunde: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">51.32</subfield><subfield code="j">Werkstoffmechanik</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">24</subfield><subfield code="j">2016</subfield><subfield code="e">9</subfield><subfield code="h">684-686</subfield><subfield code="g">3</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">570</subfield></datafield></record></collection>
|
| score |
7.399476 |